Abstract | BACKGROUND: METHODS: Clinical history of 7 patients with POTS who were treated with SCIG or PLEX was reviewed. Response to treatment was assessed using COMPASS 31 and functional ability scale (FAS), completed by patients retrospectively, pre- and 3-12 months post-treatment with SCIG or PLEX. RESULTS: All patients improved following SCIG or PLEX with an average 50% reduction in COMPASS 31 score and 217% increase in FAS scores. Six out of seven patients were able to reduce or discontinue oral medications for POTS, and five patients were able to return to work or school. Four patients had skin biopsy or quantitative sudomotor axon reflex test (QSART)-proven small fiber neuropathy, and five had various positive antibodies at low titers. CONCLUSION: Patients with severe, treatment-refractory POTS experienced significant functional improvement with reduction in the autonomic symptoms following immunotherapy with SCIG or PLEX. Randomized controlled trials of SCIG and/or PLEX are needed to determine the efficacy and safety of these long-term therapies in patients with POTS.
|
Authors | Katrina Kesterson, Jill Schofield, Svetlana Blitshteyn |
Journal | Journal of neurology
(J Neurol)
Vol. 270
Issue 1
Pg. 233-239
(Jan 2023)
ISSN: 1432-1459 [Electronic] Germany |
PMID | 36008726
(Publication Type: Case Reports, Journal Article)
|
Copyright | © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. |
Chemical References |
|
Topics |
- Humans
- Postural Orthostatic Tachycardia Syndrome
(therapy, complications, diagnosis)
- Retrospective Studies
- Immunotherapy
- Plasmapheresis
- Immunoglobulins
|